Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0885432 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0885432 | 1 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0885432 | 1 | 1 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0885432 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0885432 | 1 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0885432 | 1 | 0.5 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0885432 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0386552 | 0 | 0.5 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0885432 | 1 | 1 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0885432 | 1 | 1 |
Brugia malayi | flavodoxin family protein | 0.0885432 | 1 | 1 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0885432 | 1 | 1 |
Brugia malayi | FAD binding domain containing protein | 0.0885432 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.049888 | 0.22516 | 0.22516 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0812329 | 0.853467 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0885432 | 1 | 0.5 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0885432 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0885432 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0885432 | 1 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0885432 | 1 | 1 |
Chlamydia trachomatis | sulfite reductase | 0.0571982 | 0.371693 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0885432 | 1 | 1 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0885432 | 1 | 1 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0571982 | 0.371693 | 0.371693 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0885432 | 1 | 0.5 |
Leishmania major | p450 reductase, putative | 0.0885432 | 1 | 1 |
Trypanosoma cruzi | p450 reductase, putative | 0.0885432 | 1 | 0.5 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0386552 | 0 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0885432 | 1 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0812329 | 0.853467 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | = 199 nM | Antiplasmodial activity against Plasmodium falciparum infected in human blood cells assessed as inhibition of proliferation | ChEMBL. | 25147599 |
EC50 (functional) | = 1108 nM | Antiplasmodial activity against Plasmodium yoelii infected in liver cells assessed as inhibition of proliferation | ChEMBL. | 25147599 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium yoelii | ChEMBL23 | 25147599 | |
Plasmodium falciparum | ChEMBL23 | 25147599 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.